Phoenix Biotech Acquisiti... (PBAX)
NASDAQ: PBAX
· Real-Time Price · USD
5.85
0.37 (6.75%)
At close: Feb 14, 2024, 9:56 PM
Company Description
Phoenix Biotech Acquisition Corp. does not have significant operations.
The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses.
It engages in identifying and acquiring a business that focuses on the healthcare or healthcare related industries in the United States and Europe.
The company was incorporated in 2021 and is based in Oakland, California.
Phoenix Biotech Acquisition Corp.
| Country | United States |
| IPO Date | Nov 30, 2021 |
| Industry | Shell Companies |
| Sector | Financial Services |
| Employees | n/a |
| CEO | Christopher B. Ehrlich |
Contact Details
Address: 2201 Broadway Oakland, California United States | |
| Website | n/a |
Stock Details
| Ticker Symbol | PBAX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001870404 |
| CUSIP Number | 71902K105 |
| ISIN Number | US71902K1051 |
| Employer ID | 87-1088814 |
| SIC Code | 6770 |
Key Executives
| Name | Position |
|---|---|
| Christopher B. Ehrlich M.B.A. | Chief Executive Officer & Director |
| Daniel E. Geffken M.B.A. | Chief Financial Officer |
| Dr. Douglas Carl Fisher M.B.A., M.D. | President |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Aug 11, 2025 | S-3 | Filing |
| Jul 28, 2025 | S-8 | Filing |
| Jul 25, 2025 | 424B3 | Filing |
| Jul 21, 2025 | S-1 | Filing |
| Jul 18, 2025 | 8-K | Current Report |
| Jul 14, 2025 | 424B3 | Filing |
| Jul 14, 2025 | 8-K | Current Report |
| Jul 08, 2025 | 8-K | Current Report |
| Jul 02, 2025 | 424B3 | Filing |